Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
05/2000
05/24/2000EP1002862A1 Methods of diagnosing or treating neurological diseases
05/24/2000EP1002120A1 Chimeric adenoviral vectors
05/24/2000EP1002119A1 Targeted hsv vectors
05/24/2000EP1002110A1 Immune responses against hpv antigens elicited by compositions comprising an hpv antigen and a stress protein or an expression vector capable of expression of these proteins
05/24/2000EP1002108A2 Use of mhc class ii ligands as adjuvant for vaccination and of lag-3 in cancer treatment
05/24/2000EP1002103A1 A human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof
05/24/2000EP1002099A1 Synaptojanin isoform
05/24/2000EP1002092A1 Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
05/24/2000EP1002091A1 Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue
05/24/2000EP1002082A2 Transcriptional silencer protein nrf
05/24/2000EP1002081A2 Delayed progression to aids by a missense allele of the ccr2 gene
05/24/2000EP1002079A2 Novel inhibitor of cellular proliferation
05/24/2000EP1002078A1 Method enabling readministration of aav vector via immunosuppresion of host
05/24/2000EP1002077A1 Secreted proteins encoded by human chromosome 13
05/24/2000EP1002075A1 Adipocyte-specific protein homologs
05/24/2000EP1002073A2 Cell activation process and reagents therefor
05/24/2000EP1002068A1 Mutations in the myostatin gene cause double-muscling in mammals
05/24/2000EP1001987A2 Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
05/24/2000EP1001985A1 Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
05/24/2000EP1001984A1 NOVEL ESTROGEN RECEPTOR $g(b) AND ISOFORMS
05/24/2000EP1001983A1 NOVEL ESTROGEN $g(b) RECEPTOR AND ISOFORMS
05/24/2000EP1001978A1 Angiotensin derivatives
05/24/2000EP1001966A1 A senescence gene and its use in the treatment of cancer and other diseases
05/24/2000EP1001795A1 Vasoprotective recombinant adenovirus vector containing a human tfpi gene
05/24/2000EP1001750A1 Stable particulate complexes with neutral or negative globale charge of lamellar structure
05/24/2000CN1254378A Adneovirus-mediated intratumoral delivery of angiogenesis antagonist for treatment of tumors
05/24/2000CN1254376A 端粒酶逆转录酶 Telomerase reverse transcriptase
05/24/2000CN1254294A Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
05/24/2000CN1254292A Anti-helicobacter vaccine composition for use by subdiahragmatic systemic route, and combined mucosal/parenteral immunization method
05/24/2000CN1052756C Series of cDNA for improving tumour cells differentiation and carrier for eucaryon expression thereof
05/23/2000US6066726 Neuron-specific transcriptional promoter
05/23/2000US6066724 Human endometrial specific steroid-binding factor I, II and III
05/23/2000US6066717 RsbW-1 protein
05/23/2000US6066626 Supplying active human galactosidase to cells
05/23/2000US6066625 Enzyme inhibitor; modulators of gene expression
05/23/2000US6066624 Gene therapy for solid tumors using adenoviral vectors comprising suicide genes and cytokine genes
05/23/2000US6066502 Endothelin converting enzyme (ECE)
05/23/2000US6066498 Compositions for the treatment and diagnosis of immune disorders
05/23/2000US6066478 Dna encoding a hybrid protein including a recombinase able to recognize a recombination sequence and a linking region recognized by a ligand; for complementation cells used to produce viral vectors used in gene therapy
05/23/2000US6066322 Administering antibody to treat asthma; treating helper t-cell mediated conditions
05/23/2000US6066319 Administering membrane attack complex (mac) transmembrane channel forming agent which is an antibody simultaneously therewith an effective amount of a therapeutic or diagnostic agent
05/23/2000US6066318 Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
05/23/2000US6066123 Enhancement of bioavailability by use of focused energy delivery to a target tissue
05/23/2000CA2165162C Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
05/19/2000CA2254444A1 Cell line for producing repressor proteins
05/18/2000WO2000028323A1 Methods for identifying modulators of bs69 activity
05/18/2000WO2000028062A1 Novel system for regulating transgene expression
05/18/2000WO2000028061A2 Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
05/18/2000WO2000028060A2 Cells for the production of helper dependent adenoviral vectors
05/18/2000WO2000028059A1 Adenovirus-mediated gene therapy
05/18/2000WO2000028048A1 Novel plasmids for use in medicine and method of producing same
05/18/2000WO2000028042A1 Use of an inducible gene for the enzyme cyclooxygenase to lower intraocular pressure
05/18/2000WO2000028041A1 Delivery of superoxide dismutase to neuronal cells
05/18/2000WO2000028039A2 Identification of senv genotypes
05/18/2000WO2000028038A2 Virulence genes and proteins, and their use
05/18/2000WO2000028037A1 CATFIIIA CANDIDA ALBICANS tfIIIA GENE (CatfIIIA) AND THE CODED CATFIIIA PROTEIN
05/18/2000WO2000028031A2 Mitogenic regulators
05/18/2000WO2000028027A2 Corticosteroid synthesis-associated genes
05/18/2000WO2000028024A1 htfIIIA HUMAN GENE AND CODED hTFIIIA PROTEIN
05/18/2000WO2000028020A2 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
05/18/2000WO2000028019A2 Antisense oligomer
05/18/2000WO2000028013A2 Gene expression modulated by activation of microglia or macrophages
05/18/2000WO2000028011A2 Fk506-based regulation of biological events
05/18/2000WO2000028010A2 The genetic determination of genes and its use for the prophylaxis and therapy of diseases
05/18/2000WO2000028004A1 Virus vectors and methods of making and administering the same
05/18/2000WO2000028003A1 Avipox vector coding an hiv antigen and a cytokine
05/18/2000WO2000027883A2 A method of treating tumors using fas-induced apoptosis
05/18/2000WO2000027879A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof
05/18/2000WO2000027877A1 Novel major facilitator superfamily polypeptide, uses thereof and nucleic acids encoding same
05/18/2000WO2000027874A2 Nucleic acids encoding transferrin receptor-like proteins and products related thereto
05/18/2000WO2000027870A1 Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof
05/18/2000WO2000027868A2 Connective tissue growth factor (ctgf) and methods of use
05/18/2000WO2000027864A1 CHROMOSOME 17p-LINKED PROSTATE CANCER SUSCEPTIBILITY GENE
05/18/2000WO2000027432A1 USE OF AN ENTEROBACTERIUM PROTEIN OmpA FOR SPECIFIC TARGETING TOWARDS ANTIGEN-PRESENTING CELLS
05/18/2000WO2000027427A1 trmD
05/18/2000WO2000027426A1 Method for enhancing proliferation of inner ear hair cells using ligands for her2 and/or her3 receptors
05/18/2000WO2000027422A2 Methods and compositions for treating or preventing peripheral neuropathies
05/18/2000WO2000027414A2 Inhibition of the formation of vascular hyperpermeability
05/18/2000WO2000027409A1 Production of a biological factor and creation of an immunologically privileged environment using genetically altered sertoli cells
05/18/2000WO2000027361A1 Stabilized nucleic acid compositions and methods of preparation and use thereof
05/18/2000WO2000027198A1 Retroviral vectors encoding interferon alpha and uses thereof
05/18/2000WO2000009734A3 Methods and compositions for use in spliceosome mediated rna trans-splicing
05/18/2000WO2000009730A3 Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
05/18/2000WO2000008193A3 Latency-active regulatory sequences of herpesviruses and latency-inactive herpesvirus for gene transfer
05/18/2000WO2000008141A3 Short oligonucleotides for the inhibition of vegf expression
05/18/2000WO2000008140A3 Antisense oligonucleotides for the inhibition of vegf expression
05/18/2000DE19850718C1 Zellpermeabilität-vermittelndes Polypeptid Cell permeability-mediating polypeptide
05/18/2000CA2351019A1 Htfiiia human gene and coded htfiiia protein
05/18/2000CA2351017A1 Catfiiia candida albicans tfiiia gene (catfiiia) and the coded catfiiia protein
05/18/2000CA2350183A1 Use of an enterobacterium protein ompa for specific targeting towards antigen-presenting cells
05/18/2000CA2350182A1 Connective tissue growth factor (ctgf) and methods of use
05/18/2000CA2350087A1 Chromosome 17p-linked prostate cancer susceptibility gene
05/18/2000CA2350086A1 Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
05/18/2000CA2349951A1 Platelet-derived growth factor d, dna coding therefor, and uses thereof
05/18/2000CA2349859A1 Stabilized nucleic acid compositions and methods of preparation and use thereof
05/18/2000CA2349761A1 Corticosteroid synthesis-associated genes
05/18/2000CA2349498A1 Methods and compositions for treating or preventing peripheral neuropathies
05/18/2000CA2349496A1 Delivery of superoxide dismutase to neuronal cells
05/18/2000CA2349445A1 Antisense oligomer
05/18/2000CA2348699A1 Virulence genes and proteins, and their use
1 ... 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 ... 870